Current Urology最新文献

{"title":"From bench to bedside: A narrative review of regenerative medicine approaches for postprostatectomy incontinence.","authors":"W Garrett Haffke, Thomas R Wong, Runzhuo Ma, Laura E Davis, Ilaha Isali","doi":"10.1097/CU9.0000000000000333","DOIUrl":"10.1097/CU9.0000000000000333","url":null,"abstract":"<p><p>Postprostatectomy urinary incontinence (PPUI) is a prevalent complication following radical prostatectomy, with long‑term incontinence affecting up to one‑third of patients. Conventional treatments are limited by inconsistent efficacy, side effects or invasiveness, indicating demand for alternative therapies. This narrative review assessed clinical evidence of regenerative therapies, especially autologous stem cell approaches, for PPUI. We searched multiple databases for studies published between 2010 and 2024; eligible articles were clinical trials using stem cell therapies for PPUI, while non‑PPUI incontinence or non‑clinical outcome studies were excluded. Eight studies enrolling 311 patients were included: six used adipose‑derived stem cells (ADSCs) and two used muscle‑derived cells, administered via periurethral, transurethral or surgical implantation. Overall, 43.7% of patients achieved continence improvement, with efficacy ranging from 0% to 100% across studies; adverse events were mostly mild and self‑limiting. However, heterogeneity in study design, small sample sizes, inconsistent outcomes and short follow‑up restricted generalizability. Regenerative cell therapies, particularly ADSCs, are promising and well‑tolerated for PPUI. ADSCs are superior in easy harvest, scalability and multilineage differentiation. Although early data are encouraging, large‑scale, long‑term studies are required to confirm efficacy, optimize delivery and evaluate long‑term safety and durability.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"206-212"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in urinary incontinence among women in the United States from 2001 to 2023.","authors":"Mengting Liu, Zhongyan Xu, Minjing Chang, Jun Qiao","doi":"10.1097/CU9.0000000000000347","DOIUrl":"10.1097/CU9.0000000000000347","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"253-256"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implantable bladder sensors for real-time urodynamics: A systematic review of preclinical and clinical evidence in neuro-urology.","authors":"Kirolos Eskandar","doi":"10.1097/CU9.0000000000000331","DOIUrl":"10.1097/CU9.0000000000000331","url":null,"abstract":"<p><strong>Background: </strong>Catheter-based urodynamic studies remain the standard for diagnosing lower urinary tract dysfunction, but are limited by discomfort, infection risk, and restricted monitoring duration. Emerging implantable bladder sensors offer the potential for real-time wireless pressure monitoring without the need for catheters, with promising applications in neurology. This study was aimed to systematically review and compare the performance, safety, and translational readiness of intravesical and submucosal implantable bladder sensors used for real-time urodynamic assessments in preclinical and clinical studies.</p><p><strong>Materials and methods: </strong>A systematic literature search was conducted in PubMed, Scopus, and IEEE Xplore from their inception to July 10, 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies that evaluated wireless implantable bladder pressure sensors in animal or human models were included. Data on the pressure fidelity, biocompatibility, implantation site, and signal stability were extracted and compared.</p><p><strong>Results: </strong>Four studies met the inclusion criteria: 3 preclinical studies (rabbit or pig) and 1 human feasibility trial. Intravesical sensors showed superior pressure fidelity (correlation coefficients up to r = 0.885), minimal error (±1 cm H₂O), and favorable safety with no adverse effects. In humans, the UroMonitor device demonstrated an event-detection accuracy of 98% and was well tolerated. Submucosal devices achieved high event-specific correlations (r = 0.75-0.94) but were limited by erosion and signal degradation. Heterogeneity in sensor design, implantation duration, and biocompatibility has limited direct comparisons.</p><p><strong>Conclusions: </strong>Intravesical implantable sensors demonstrated higher accuracy, safety, and translational readiness than submucosal alternatives. The success of the UroMonitor in human feasibility studies underscores its potential for catheter-free ambulatory bladder pressure monitoring. Future studies should focus on long-term implantation, artificial intelligence integration, and comparative trials using conventional urodynamics.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"235-243"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare urologic malignancies in solid organ transplant recipients.","authors":"Ignacio Gondolesi, Michael A Palese","doi":"10.1097/CU9.0000000000000352","DOIUrl":"10.1097/CU9.0000000000000352","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"260-262"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of a young girl with genital manifestations of Proteus syndrome.","authors":"Donald Dominick Lema, Musa Raymond Majura, Magdalena Benitho Mahenge","doi":"10.1097/CU9.0000000000000338","DOIUrl":"10.1097/CU9.0000000000000338","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"265-266"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of miR-34a/KLF4 axis in podocyte injury and obesity-related glomerulopathy with preliminary observations in clear cell renal cell carcinoma.","authors":"Jing Li, Peng Zhao, Qiulan Lv, Guangqun Xing, Gang Liu","doi":"10.1097/CU9.0000000000000344","DOIUrl":"10.1097/CU9.0000000000000344","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the role of miR34a in obesity-related glomerular disease using an experimental mouse model induced by a high-fat diet and a podocyte injury model induced by palmitic acid.</p><p><strong>Materials and methods: </strong>An obese mouse model was established by high-fat feeding, followed by analysis of renal pathology, immunohistochemistry, and detection of miR34a and Krüppel-like factor 4 (KLF4) levels. In vitro experiments involved treating podocytes with varying concentrations of palmitic acid, performing Oil Red O staining, assessing related indicators and apoptosis, and transfection with miR34a mimics or inhibitors to evaluate their effects. The target relationship was validated using a luciferase assay. The differential expression of miR34a in clear cell renal cell carcinoma (ccRCC) and adjacent normal tissue was detected using RT-qPCR.</p><p><strong>Results: </strong>A high-fat diet was successfully used to establish an obese mouse model, which led to a significantly increased glomerular volume. Renal tissues exhibited decreased KLF4 and nephrin levels and increased Bak and cleaved CASP9 levels. miR34a was negatively correlated with KLF4 and positively correlated with Bak, suggesting the potential induction of apoptosis through KLF4. Cell experiments demonstrated that palmitic acid upregulated miR34a, downregulated KLF4, and induced podocyte apoptosis. Furthermore, miR34a mimics exacerbated apoptosis, whereas miR34a inhibitors alleviated apoptosis. A dual-luciferase assay confirmed that miR34a targeted and inhibited KLF4 expression. miR-34a expression was upregulated in ccRCC compared with adjacent normal renal tissues, and this tendency was more prominent in obese patients.</p><p><strong>Conclusions: </strong>Elevated miR34a levels may contribute to podocyte injury by inhibiting KLF4, thereby promoting the progression of obesity-related glomerulopathy. miR34a may also be related to the pathogenesis of ccRCC, especially in obese patients.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"244-252"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The regulatory mechanism and clinical significance of RNA editing in prostate cancer.","authors":"Shoukang Li, Anshu Li, Yongming Huang, Youjia Wang, Meiyin Fan, Xiaoying Jiang, Kaijian Bing, Jiaqian Liang, Keshan Wang, Zhi Xu, Liyang Wang","doi":"10.1097/CU9.0000000000000353","DOIUrl":"10.1097/CU9.0000000000000353","url":null,"abstract":"<p><p>Prostate cancer (PCa) is one of the most common malignancies in men and remains particularly challenging as it progresses to the castration-resistant stage. Increasing evidence indicates that dysregulated RNA editing plays an active role in PCa progression and resistance to therapy. Among these modifications, adenosine-to-inosine editing catalyzed by adenosine deaminase acting on RNA 1 (ADAR1) alters transcripts, such as androgen receptor (AR) and antizyme inhibitor 1, promoting androgen-independent growth, metastasis, and immune evasion. Conversely, cytidine-to-uridine editing mediated by apolipoprotein B mRNA editing catalytic polypeptide-like 3 (APOBEC3) enzymes contributes to genomic instability. For example, APOBEC3B induces mutagenesis and resistance to AR-targeted therapy, and APOBEC3C functions as a context-dependent tumor suppressor that is transcriptionally repressed by the AR in advanced disease. Clinically, RNA editing signatures, including APOBEC3C expression levels, have shown promise as biomarkers for risk stratification, disease monitoring, and prognosis. Therapeutically, inhibition of ADAR1 or APOBEC3B, restoration of APOBEC3C activity, and site-specific corrective RNA editing using the CRISPR-ADAR2 platform represent emerging precision strategies. Ongoing development of small-molecule inhibitors, oligonucleotide-based modulators, and liquid biopsy-based detection methods further highlights the translational relevance of RNA editing in PCa. Future research should focus on improving editing specificity, minimizing off-target effects, and validating these biomarkers and therapeutic targets in clinical settings to fully realize the diagnostic and therapeutic potential of RNA editing in the precise management of prostate cancer.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"195-205"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Does preoperative tamsulosin facilitate semirigid ureteroscopic management of lower ureteric calculi? A prospective, randomized double-blind study.","authors":"Hüsnü Tokgöz, Özlem Tokgöz","doi":"10.1097/CU9.0000000000000325","DOIUrl":"10.1097/CU9.0000000000000325","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"257-258"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial comment on Chinese expert consensus on prostate-pelvic syndrome.","authors":"Sergey Kravchick","doi":"10.1097/CU9.0000000000000341","DOIUrl":"10.1097/CU9.0000000000000341","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"259"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in delivery systems for in vivo chimeric antigen receptor T-cell therapy in urological diseases.","authors":"Yuxiao Li, Wen Zhang, Dongqi Tang","doi":"10.1097/CU9.0000000000000349","DOIUrl":"10.1097/CU9.0000000000000349","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T-cell therapy is a new type of highly precise and targeted immunotherapy for urological diseases. It has demonstrated significant therapeutic potential in chronic and autoimmune kidney diseases such as renal fibrosis and membranous nephropathy. However, owing to its high cost, low efficiency, and serious side effects, such as cytokine storm syndrome, a new generation of drugs has emerged to solve these problems. In vivo CAR T-cell therapy is a treatment method that directly modifies specific cells within the patient's body through various delivery systems. Nonviral vectors (nanoparticles and exosomes) and viral vectors (adeno-associated viruses and lentiviruses) can be engineered to achieve better therapeutic effects. By taking advantage of different delivery systems and minimizing their drawbacks, in vivo CAR T-cell therapy can improve the stability and targeting ability, reduce immunogenicity, and minimize side effects. This review summarizes the mechanisms of action and clinical applications of various delivery systems used in in vivo CAR T-cell therapy, highlighting their potential in the treatment of urological diseases. Through a deeper understanding of the construction and optimization of well-designed platforms, the development of optimal delivery systems has valuable implications for the establishment of new pharmaceuticals for in vivo CAR T-cell therapy in urological diseases.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 4","pages":"219-234"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}